Alpine Immune Sciences 미래 성장

Future 기준 확인 2/6

Alpine Immune Sciences 의 수익은 연간 9.9% 감소할 것으로 예상되는 반면, 연간 수익은 34.2% 로 증가할 것으로 예상됩니다. 34.2% 연간. EPS는 연간 11% 만큼 쇠퇴할 것으로 예상됩니다. 자기자본이익률은 3년 후 -78.4% 로 예상됩니다.

주요 정보

-9.9%

수익 성장률

-11.0%

EPS 성장률

Biotechs 수익 성장	42.4%
매출 성장률	34.2%
향후 자기자본 수익률	-78.4%
애널리스트 커버리지	Good
마지막 업데이트	17 May 2024

최근 미래 성장 업데이트

업데이트 없음

Recent updates

수익 및 매출 성장 예측

DB:34LA - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	10	-149	-173	-150	7
12/31/2025	20	-110	-140	-113	8
12/31/2024	18	-97	-96	-91	7
3/31/2024	57	-37	-81	-81	N/A
12/31/2023	59	-32	-79	-79	N/A
9/30/2023	31	-57	-77	-77	N/A
6/30/2023	29	-59	-78	-77	N/A
3/31/2023	26	-64	-76	-75	N/A
12/31/2022	30	-58	-44	-44	N/A
9/30/2022	32	-54	-42	-42	N/A
6/30/2022	32	-54	4	5	N/A
3/31/2022	34	-47	6	6	N/A
12/31/2021	23	-50	-15	-15	N/A
9/30/2021	25	-42	-10	-10	N/A
6/30/2021	18	-34	-46	-45	N/A
3/31/2021	11	-33	23	24	N/A
12/31/2020	9	-28	29	30	N/A
9/30/2020	5	-28	33	34	N/A
6/30/2020	3	-33	28	29	N/A
3/31/2020	3	-35	-35	-34	N/A
12/31/2019	2	-42	-36	-35	N/A
9/30/2019	1	-47	-39	-39	N/A
6/30/2019	1	-48	-36	-36	N/A
3/31/2019	0	-44	-35	-35	N/A
12/31/2018	1	-36	-29	-28	N/A
9/30/2018	1	-30	-25	-25	N/A
6/30/2018	1	-15	-23	-22	N/A
3/31/2018	1	-11	-19	-19	N/A
12/31/2017	2	-8	N/A	-17	N/A
9/30/2017	2	-5	N/A	-13	N/A
6/30/2017	3	-7	N/A	-9	N/A
3/31/2017	3	-3	N/A	-6	N/A
12/31/2016	3	-1	N/A	-4	N/A
12/31/2015	0	0	N/A	5	N/A

애널리스트 미래 성장 예측

수입 대 저축률: 34LA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: 34LA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: 34LA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: 34LA 의 수익(연간 34.2% ) German 시장( 5.6% 보다 빠르게 성장할 것으로 예상됩니다. 5.6% 연간).

고성장 수익: 34LA 의 수익(연간 34.2% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 34LA (는) 3년 내에 수익성이 없을 것으로 예상됩니다.

Alpine Immune Sciences 미래 성장

Future 기준 확인 2/6

주요 정보

최근 미래 성장 업데이트

Recent updates

Alpine Immune Sciences Files Form 15

Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from NASDAQ Composite Index

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) completed the acquisition of Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders.

Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from S&P TMI Index

First quarter 2024 earnings released: US$0.28 loss per share (vs US$0.28 loss in 1Q 2023)

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion.

Alpine Immune Sciences, Inc Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024

Full year 2023 earnings released: US$0.64 loss per share (vs US$1.73 loss in FY 2022)

Alpine Immune Sciences, Inc. to Report Fiscal Year 2023 Results on Mar 18, 2024

Insufficient new directors

Insufficient new directors

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.42 loss in 3Q 2022)

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $149.9968 million.

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $110 million.

Alpine Immune Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Alpine Immune Sciences, Inc. Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis

New major risk - Share price stability

Alpine Immune Sciences, Inc. Announces Appointment of Wolfgang Dummer as Chief Medical Officer

Alpine Immune Sciences, Inc. Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinical Study (RUBY-3)

Second quarter 2023 earnings released: US$0.27 loss per share (vs US$0.60 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.28 loss per share (vs US$0.25 loss in 1Q 2022)

Full year 2022 earnings released: US$1.73 loss per share (vs US$1.98 loss in FY 2021)

Insufficient new directors

Insufficient new directors

Alpine Immune Sciences, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Alpine Immune Sciences Terminates Enrollment of Davoceticept Clinical Studies (NEON-1 and NEON-2)

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $100.0041 million.

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $100.0041 million.

Alpine Immune Sciences, Inc. Provides Clinical Updates for Its Two Wholly Owned Programs, ALPN-303 and davoceticept

Second quarter 2022 earnings released: US$0.60 loss per share (vs US$0.46 loss in 2Q 2021)

Alpine Immune Sciences, Inc. Announces Board Changes

Alpine Immune Sciences Appoints Andrew S. Sandler as Chief Medical Officer

Alpine Immune Sciences, Inc. Announces Update on ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases, at EULAR 2022

Alpine Immune Sciences, Inc. Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab

Alpine Immune Sciences, Inc. Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab

First quarter 2022 earnings released: US$0.25 loss per share (vs US$0.45 loss in 1Q 2021)

Alpine Immune Sciences, Inc., Annual General Meeting, Jun 16, 2022

Insufficient new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Alpine Immune Sciences Announces Oral Presentation at the 2022 AACR Annual Meeting

Insufficient new directors

Alpine Immune Sciences, Inc. announced that it expects to receive $15 million in funding from Horizon Therapeutics Public Limited Company

Insufficient new directors

Third quarter 2021 earnings released: US$0.55 loss per share (vs US$0.28 loss in 3Q 2020)

Independent Director recently bought €84k worth of stock

Second quarter 2021 earnings released: US$0.46 loss per share (vs US$0.53 loss in 2Q 2020)

Alpine Immune Sciences Announces First Patient Dosed in Synergy, Alpn-101 Phase 2 Lupus Clinical Trial and $45 Million in Development Milestones Achieved Under Abbvie Collaboration

Alpine Immune Sciences Announces ALPN-202 Clinical Data Presented at 2021 American Society of Clinical Oncology Virtual Annual Meeting

Alpine Immune Sciences, Inc. Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting

First quarter 2021 earnings released: US$0.45 loss per share (vs US$0.30 loss in 1Q 2020)

Full year 2020 earnings released: US$1.34 loss per share (vs US$2.28 loss in FY 2019)

Alpine Immune Sciences, Inc. to Report Q4, 2020 Results on Mar 18, 2021

Alpine Immune Sciences, Inc. Announces Executive Changes

New 90-day high: €11.80

Alpine Immune Sciences Appoints Natasha A. Hernday to its Board of Directors

New 90-day high: €7.70

Independent Director recently bought €68k worth of stock

Third quarter 2020 earnings released: US$0.28 loss per share

Revenue misses expectations

Alpine Immune Sciences, Inc. to Report Q3, 2020 Results on Nov 12, 2020

First half earnings released

Alpine Immune Sciences, Inc. announced that it has received $60.000012 million in funding from a group of investors

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견